XOSPATA Was Compared to Chemotherapy
XOSPATA was studied in comparison to chemotherapy in people whose AML had come back or had not improved after previous treatment. People in the study were positive for a FLT3 mutation, as determined by a bone marrow or blood test.
The final set of results in the study compared the rate of overall survival in 247 people who had taken XOSPATA with 124 people who received chemotherapy.
The term overall survival refers to the length of time during the study that people stayed alive beyond the start of treatment.